TW202300527A - 使用ｇｒｅｍ１拮抗劑治療疾病的方法 - Google Patents

使用ｇｒｅｍ１拮抗劑治療疾病的方法 Download PDF

Info

Publication number
TW202300527A
TW202300527A TW111109016A TW111109016A TW202300527A TW 202300527 A TW202300527 A TW 202300527A TW 111109016 A TW111109016 A TW 111109016A TW 111109016 A TW111109016 A TW 111109016A TW 202300527 A TW202300527 A TW 202300527A
Authority
TW
Taiwan
Prior art keywords
seq
grem1
cancer
cdata
variable region
Prior art date
Application number
TW111109016A
Other languages
English (en)
Chinese (zh)
Inventor
鶴 朱
雪明 錢
高維強
程姹萍
王金名
孫迪
Original Assignee
上海交通大學
中國大陸商蘇州創勝醫藥集團有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海交通大學, 中國大陸商蘇州創勝醫藥集團有限公司 filed Critical 上海交通大學
Publication of TW202300527A publication Critical patent/TW202300527A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111109016A 2021-03-11 2022-03-11 使用ｇｒｅｍ１拮抗劑治療疾病的方法 TW202300527A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
WOPCT/CN2021/080142 2021-03-11
CN2021080142 2021-03-11
WOPCT/CN2022/076516 2022-02-16
CN2022076516 2022-02-16

Publications (1)

Publication Number Publication Date
TW202300527A true TW202300527A (zh) 2023-01-01

Family

ID=83226314

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111109016A TW202300527A (zh) 2021-03-11 2022-03-11 使用ｇｒｅｍ１拮抗劑治療疾病的方法

Country Status (11)

Country Link
US (1) US20240190950A1 (https=)
EP (1) EP4304646A4 (https=)
JP (1) JP2024513692A (https=)
KR (1) KR20230156936A (https=)
CN (1) CN116940380A (https=)
AU (1) AU2022233762A1 (https=)
BR (1) BR112023018204A2 (https=)
CA (1) CA3213121A1 (https=)
MX (1) MX2023010594A (https=)
TW (1) TW202300527A (https=)
WO (1) WO2022188856A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504124A (ja) * 2021-01-18 2024-01-30 スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド 新規の抗グレムリン１抗体
WO2024213066A1 (en) * 2023-04-13 2024-10-17 Suzhou Transcenta Therapeutics Co., Ltd. Combination therapies involving grem1 antagonists for treatment of cancer
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用
CN119746060B (zh) * 2025-03-07 2025-09-16 南昌大学第一附属医院 一种树突状细胞疫苗制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6339063B2 (ja) * 2012-03-15 2018-06-06 エスエヌユー アールアンドディービー ファウンデーション グレムリン−１に対する抗体
ES2898620T3 (es) * 2013-03-14 2022-03-08 Regeneron Pharma Anticuerpos humanos contra GREM 1
US10844051B2 (en) * 2015-07-22 2020-11-24 The Royal Institution For The Advancement Of Learning/Mcgill University Substituted oxazoles for the treatment of cancer
GB201621635D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
PL3806898T3 (pl) * 2018-06-18 2026-02-23 UCB Biopharma SRL Antagonista gremlin-1 do zastosowania w leczeniu nowotworu
JP2024504124A (ja) * 2021-01-18 2024-01-30 スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド 新規の抗グレムリン１抗体

Also Published As

Publication number Publication date
JP2024513692A (ja) 2024-03-27
BR112023018204A2 (pt) 2023-10-24
US20240190950A1 (en) 2024-06-13
KR20230156936A (ko) 2023-11-15
CN116940380A (zh) 2023-10-24
WO2022188856A1 (en) 2022-09-15
EP4304646A4 (en) 2025-05-28
EP4304646A1 (en) 2024-01-17
CA3213121A1 (en) 2022-09-15
MX2023010594A (es) 2023-09-25
AU2022233762A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
CN111363041B (zh) 新型抗-pd-l1抗体
CN101939336B (zh) Axl抗体
JP5808052B2 (ja) Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
AU2015240599B2 (en) Humanized antibodies that bind LGR5
TW202300527A (zh) 使用ｇｒｅｍ１拮抗劑治療疾病的方法
US20120117670A1 (en) Humanized axl antibodies
AU2015313268B2 (en) Cancer-cell-specific antibody, anticancer agent, and cancer testing method
KR102644658B1 (ko) 모노클로날 항체 항-fgfr4
WO2022152290A1 (en) Novel anti-gremlin1 antibodies
US20230414778A1 (en) COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY
JP6041333B2 (ja) 抗腫瘍剤
WO2011007853A1 (ja) 癌特異的アイソフォームに対するモノクローナル抗体
AU2018378668B2 (en) Anti-RSPO3 antibodies
RU2853818C9 (ru) Способ лечения заболеваний с применением антагонистов GREMLIN1
RU2853818C1 (ru) Способ лечения заболеваний с применением антагонистов GREMLIN1
HK40094175A (zh) 使用grem1拮抗剂治疗疾病的方法
US20250282865A1 (en) COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-SIRPa ANTIBODY
HK40117039A (en) Combination of antibody-drug conjugate and anti-sirpalpha antibody
CA3252302A1 (en) Combination of antibody-drug conjugate and anti-sirp.alpha. antibody
TW202214251A (zh) 對抗癌劑之抵抗性改善劑
BR112020006860A2 (pt) composição para depleção de células t citotóxicas